LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3051% below fair value
$3.82−0.31 (-7.51%)
Close on Nov 16, 2026Market cap $120.03MP/E –Yield –
LENZ Therapeutics total assets
Total assets on the balance sheet at the end of each period.
LENZ Therapeutics's total assets was $236.60M at Jun 30, 2026. For fiscal 2025 it was $305.88M, up 42.1% from the year before. The highest annual figure on record is $401.99M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $305.88M | +42.1% |
| FY2024 | Dec 31, 2024 | $215.30M | +205.9% |
| FY2023 | Dec 31, 2023 | $70.38M | -78.1% |
| FY2022 | Dec 31, 2022 | $321.90M | -19.9% |
| FY2021 | Dec 31, 2021 | $401.99M | +1681.5% |
| FY2020 | Dec 31, 2020 | $22.56M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $236.60M | +8.9% |
| Q1 FY2026 | Mar 31, 2026 | $272.54M | +35.4% |
| Q4 FY2025 | Dec 31, 2025 | $305.88M | +42.1% |
| Q3 FY2025 | Sep 30, 2025 | $210.70M | -5.9% |
| Q2 FY2025 | Jun 30, 2025 | $217.33M | +7.3% |
| Q1 FY2025 | Mar 31, 2025 | $201.25M | -7.4% |
| Q4 FY2024 | Dec 31, 2024 | $215.30M | +205.9% |
| Q3 FY2024 | Sep 30, 2024 | $224.01M | -15.9% |
| Q2 FY2024 | Jun 30, 2024 | $202.64M | -29.4% |
| Q1 FY2024 | Mar 31, 2024 | $217.32M | -29.9% |
| Q4 FY2023 | Dec 31, 2023 | $70.38M | -78.1% |
| Q3 FY2023 | Sep 30, 2023 | $266.23M | -20.5% |
| Q2 FY2023 | Jun 30, 2023 | $287.04M | -18.9% |
| Q1 FY2023 | Mar 31, 2023 | $310.00M | -18.1% |
| Q4 FY2022 | Dec 31, 2022 | $321.90M | -19.9% |
| Q3 FY2022 | Sep 30, 2022 | $334.85M | -19.5% |
| Q2 FY2022 | Jun 30, 2022 | $353.79M | -8.6% |
| Q1 FY2022 | Mar 31, 2022 | $378.61M | +1577.9% |
| Q4 FY2021 | Dec 31, 2021 | $401.99M | – |
| Q3 FY2021 | Sep 30, 2021 | $416.15M | – |
| Q2 FY2021 | Jun 30, 2021 | $387.11M | – |
| Q4 FY2020 | Dec 31, 2020 | $22.56M | – |
See a number that looks wrong?